AN2 Therapeutics names Sarah Williams as VP, Controller and PAO; CFO Lucy Day salary reduced from Apr 2026

AN2 Therapeutics, Inc.

Sarah Williams appointed VP, Controller and Principal Accounting Officer, effective Feb 1, 2026.
Lucy Day remains CFO; base salary reduced to $223,600 from April 1, 2026 (current $335,400 until Mar 31).
Williams receives annual base salary of $310,000 with target annual bonus of 30% of base.
Day's severance eligibility reduced to 50% of plan if terminated after April 1, 2026 (non-CIC).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.